Publications by authors named "J Tuettenberg"
Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients.
Cancers (Basel)
December 2023
Glioblastoma (GB) is notoriously resistant to therapy. GB genesis and progression are driven by glioblastoma stem-like cells (GSCs). One goal for improving treatment efficacy and patient outcomes is targeting GSCs.
View Article and Find Full Text PDFEffective hemostasis is crucial in neurosurgery as anatomical and functional considerations reduce tolerance for any bleeding. The classification of bleeding severities is a necessary step to enable neurosurgeons to counteract bleeding during surgery. Even though bleeding scales are used for a variety of surgical specialties, they cannot be transferred to cranial neurosurgery without adaption, and no consensus on the nature of such a classification exists to date.
View Article and Find Full Text PDFPurpose: Preclinical studies indicated that imatinib may have single-agent activity in glioblastoma through inhibition of tyrosine kinase activity and also that it might enhance the efficacy of radiotherapy. We therefore sought to investigate clinical efficacy in patients with newly diagnosed and recurrent glioblastoma in combination with radiotherapy.
Methods: We conducted a nonrandomized, 2-arm, open-label phase II trial including patients aged 18 years or older with an ECOG performance status of 0-2 that were either newly diagnosed (arm A) with a measurable tumor (i.
Article Synopsis
- GARP is a special molecule found on activated T cells that helps the body ignore certain cells, like tumors, so they can grow without being attacked by the immune system.
- Researchers found GARP not only on these T cells but also on different types of brain tumors, like glioblastoma, which suggests it plays a role in how tumors affect the immune system.
- Since GARP seems to help tumors avoid being targeted by immune cells, scientists think it could be a good target for new treatments that use antibodies to help the body fight against brain tumors.
Long-Term Reduction of Sacroiliac Joint Pain With Peripheral Nerve Stimulation.
Oper Neurosurg (Hagerstown)
October 2017
Background: We recently demonstrated that 86% of the patients treated with peripheral nerve stimulation (PNS) for therapy-refractory sacroiliac joint (SIJ) pain were satisfied with the result after 1 year of treatment.
Objective: To investigate the long-term (up to 4 years) response rate of this novel treatment.
Methods: Sixteen consecutive patients with therapy-refractory SIJ pain were treated with PNS and followed for 4 years in 3 patients, 3 years in 6 patients, and 2 years in 1 patient.